Trimurthi has announced a significant partnership with GMBU e.V., a German research institution, to advance the large-scale production of Astaxanthin, a potent antioxidant with wide-ranging applications in the nutraceutical and pharmaceutical industries.

Key Partnership Details

• Agreement Type: Technology Transfer
• Partner: GMBU e.V., Halle (Saale), Germany
• Focus: Large-scale production of Astaxanthin
• Location: Novelix's laboratories at BTIC Park, Genome Valley, Hyderabad

Scope of Collaboration

Under this agreement, GMBU e.V. will transfer its proprietary technology and expertise for the cultivation and scale-up of Haematococcus pluvialis, the microalgae known for its high Astaxanthin content. Novelix will provide financial and infrastructural support, including:

• Algal strains
• Media components
• Laboratory equipment
• Infrastructure

Production Plans

Novelix plans to establish a GMP-certified production facility at its Techno Park site in Hyderabad to manufacture Astaxanthin in bulk. The company aims to target key markets across:

• Europe
• North America
• India

About Astaxanthin

Astaxanthin, derived from Haematococcus pluvialis, is recognized for its strong antioxidant properties and has shown promise in various health applications:

The compound is valued for its ability to preserve redox balance and mitochondrial function, potentially mitigating oxidative stress—a primary cause of chronic inflammation and degenerative diseases.

Leadership Perspectives

Dr. Enrico Ehrhardt, Head of the Department of Molecular Biology at GMBU e.V., commented on the partnership: "This is a significant milestone for GMBU e.V. as we partner with Novelix Pharmaceuticals Limited, a leading Indian pharmaceutical company, for the development and scale-up of Haematococcus pluvialis. We believe this collaboration will open new avenues for joint innovation across biotechnology and healthcare domains, ensuring affordable access to high-quality therapeutic products."

Mr. Gattu Gyan Prakash, Director of Novelix Pharmaceuticals Limited, expressed enthusiasm about the collaboration: "We are thrilled to collaborate with GMBU e.V., Germany, to bring Astaxanthin production to India. This compound has tremendous therapeutic potential and commercial promise as a nutraceutical. Beyond product development, this partnership symbolizes a robust Indo-German collaboration model in biotechnology and life sciences. Novelix remains committed to advancing transformative, affordable healthcare solutions—from novel drug discovery and medical diagnostics to therapeutics and biomedical devices."

This strategic partnership underscores Novelix Pharmaceuticals' commitment to innovation in the biopharmaceutical sector and its focus on developing high-quality, affordable healthcare solutions for global markets.

Trimurthi Limited, a pharmaceutical company based in Hyderabad, has announced significant changes to its board and auditing structure following its 31st Annual General Meeting (AGM) held on September 19, 2025.

New Board Appointments

The shareholders of Trimurthi have approved the appointment of two new directors to the company's board:

1. Mr. Gattu Gnana Prakash has been appointed as a Non-Executive Non-Independent Director. Mr. Prakash, an IIT-Chennai graduate, brings over 25 years of experience in management and information technology to the board.

2. Ms. Mayuri Baidya joins as a Non-Executive Independent Director for a five-year term, effective August 14, 2025. Ms. Baidya, who holds a Post Graduate degree in Commerce from the University of Rajasthan, has extensive experience in accounting and finance.

New Secretarial Auditor

In addition to the board appointments, the shareholders approved the appointment of M/s Khushbu Kanwar & Co. as the company's Secretarial Auditor for a five-year term, from April 1, 2025, to March 31, 2030.

Voting Results

The company reported that all resolutions presented at the AGM were passed with overwhelming majority. Key voting results include:

Other Corporate Actions

The AGM also saw the approval of several other important resolutions:

1. Adoption of financial statements for the year ended March 31, 2025.
2. Re-appointment of Mr. Jivamohan Divakar Valluri as a Non-Executive Director.
3. Approval for increasing the borrowing limit under section 180(1)(c) of the Companies Act 2013.
4. Approval for creation of mortgage or charge on the company's assets under Section 180(1)(a) of the Companies Act, 2013.
5. Authorization to make investments, give loans, guarantees, and provide securities under Section 186 of the Companies Act, 2013.
6. Approval of transactions under Section 185 of the Companies Act, 2013.

These appointments and corporate actions reflect Trimurthi's commitment to strengthening its governance structure and strategic positioning in the pharmaceutical sector. The diverse experience of the new board members is expected to contribute to the company's future growth and development.